Skip to main content

Table 12 In vitro cytotoxic activity [IC50 (μM)a] of compounds (19a-j) [54]

From: Therapeutic potential of oxadiazole or furadiazole containing compounds

Compound Lung cancerA549c Breast cancer
MCF-7b MDA MB-231d
19a 9.78 ± 0.27 34.55 ± 2.34
19b 0.45 ± 0.03 1.76 ± 0.34 2.11 ± 0.21
19c 3.67 ± 0.18 2.89 ± 0.67 12.76 ± 0.81
19d 4.56 ± 0.19 2.33 ± 0.56 7.34 ± 0.26
19e 13.78 ± 1.78 12.4 ± 0.79 19.5 ± 2.11
19f 34.9 ± 2.30 15.3 ± 1.72
19g 1.03 ± 0.17 1.23 ± 0.30 1.89 ± 0.35
19h 2.45 ± 0.23 0.34 ± 0.025 1.11 ± 0.18
19i 1.89 ± 0.38 1.90 ± 0.41 3.78 ± 0.29
19j 87.5 ± 4.67 6.30 ± 0.35 22.5 ± 1.28
Doxorubicin 2.10 ± 0.14 3.12 ± 0.17 3.41 ± 0.23
  1. (–) not active, aEach data represents as mean ± S.D values. From three different experiments performed in triplicates. MCF-7: Human breast cancer cell line. cA549: Human lung cancer cell line. MDA MB-231d: Human breast cancer cell line